title: Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris.
abstract: The hemodynamic effects of nicorandil (20 mg) were compared with placebo in a double-blind study of 20 patients with angiographically proved coronary artery disease at rest before and 7, 15, 30 and 60 minutes after oral dosing. The impact of the drug on left ventricular (LV) hemodynamics and volume during exercise-induced angina was determined by repeating exercise 60 minutes after drug administration, at the same work load that reliably induced angina during control predrug exercise. At rest, nicorandil reduced all components of systemic arterial pressure without change in cardiac or stroke volume indexes or heart rate. Pulmonary artery occluded pressure was reduced without change in LV ejection fraction or systemic vascular resistance index. Effects were evident at 7 minutes and peaked at 30 minutes with attenuation at 60 minutes. Compared with control supine bicycle exercise, the drug (at 60 minutes) reduced mean systemic arterial pressure and LV filling pressure without change in cardiac stroke volume indexes and heart rate. There was a smaller increase in LV ejection fraction. These data suggested greatest impact on LV function during exercise when substantial decreases in filling pressure occurred at maintained cardiac pumping indexes.
authors.affiliation: University Department of Cardiovascular Studies, General Infirmary, Leeds, England.
authors.forename: B
authors.initials: B
authors.lastname: Silke
authors.forename: S P
authors.initials: SP
authors.lastname: Verma
authors.forename: M S
authors.initials: MS
authors.lastname: Ali
authors.forename: E
authors.initials: E
authors.lastname: Goldhammer
authors.forename: S H
authors.initials: SH
authors.lastname: Taylor
mesh_terms: D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D020108:Nicorandil; D005082:Physical Exertion; D010919:Placebos; D011897:Random Allocation; D013318:Stroke Volume / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D010919:Placebos; D014665:Vasodilator Agents; D009536:Niacinamide; D020108:Nicorandil